SynthesisFrontiers in psychiatry2026
Systematic review of animal studies on the use of herbal medicine for attention-deficit/hyperactivity disorder.
Synthesis in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Attention-deficit/hyperactivity disorder (ADHD), a common neurodevelopmental condition, often requires treatment with stimulants such as methylphenidate and nonstimulants such as atomoxetine. Despite their effectiveness, medication-related side effects, adherence and symptom control issues have increased the interest in alternative therapies, especially herbal medicine. However, existing preclinical studies vary in quality and relevance. This systematic review evaluates animal studies investigating herbal medicines for ADHD; identifies limitations in experimental models, behavioral assessments, safety evaluation, and methodological rigor; and proposes a framework to guide future research. Methods: Following PRISMA 2020 guidelines, PubMed and Web of Science were systematically searched for eligible studies published between 1995 and March 2025 that used animal models to interventions for the treatment of ADHD-like symptoms. Results: Analysis of 25 studies revealed a strong reliance on a limited range of animal models, particularly the spontaneously hypertensive rat (48%), with 88% of studies using male animals exclusively. Behavioral assessments predominantly focused on hyperactivity (72%), whereas evaluations of inattention and impulsivity were comparatively limited. Herbal interventions were associated with improvements in ADHD-like behaviors and modulation of catecholaminergic neurotransmission, including increased dopamine and norepinephrine levels in the prefrontal cortex. Additional mechanisms included activation of neurotrophic signaling pathways (brain-derived neurotrophic factor/TrkB) and suppression of proinflammatory mediators such as TNF-α and IL-1β. However, 80% of the studies did not report safety outcomes, and no study clearly described randomization or blinding procedures, limiting the translational relevance of the findings. Despite these limitations, several formulations, including the Long Mu Qing Xin mixture, An Shen Ding Zhi Ling demonstrated promising multitarget effects. Conclusion: Although herbal medicines demonstrate promising multipathway effects for ADHD, progress remains constrained by the limited diversity of animal models and narrow scope of behavioral assessments. Future research should prioritize the use of diverse models, more comprehensive assessments, and the implementation of rigorous methodological standards.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.